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Plasmodium vivax is the most common species that cause malaria outside of the African 
continent. The development of an efficacious vaccine would contribute greatly to control 
malaria. Recently, using bacterial and adenoviral recombinant proteins based on the 
P.  vivax circumsporozoite protein (CSP), we demonstrated the possibility of eliciting 
strong antibody-mediated immune responses to each of the three allelic forms of P. vivax 
CSP (PvCSP). In the present study, recombinant proteins representing the PvCSP alleles 
(VK210, VK247, and P. vivax-like), as well as a hybrid polypeptide, named PvCSP-All epi-
topes, were generated. This hybrid containing the conserved C-terminal of the PvCSP 
and the three variant repeat domains in tandem were successfully produced in the yeast 
Pichia pastoris. After purification and biochemical characterization, they were used for 
the experimental immunization of C57BL/6 mice in a vaccine formulation containing the 
adjuvant Poly(I:C). Immunization with a recombinant protein expressing all three different 
allelic forms in fusion elicited high IgG antibody titers reacting with all three different allelic 
variants of PvCSP. The antibodies targeted both the C-terminal and repeat domains of 
PvCSP and recognized the native protein on the surface of P. vivax sporozoites. More 
importantly, mice that received the vaccine formulation were protected after challenge 
with chimeric Plasmodium berghei sporozoites expressing CSP repeats of P. vivax spo-
rozoites (Pb/PvVK210). Our results suggest that it is possible to elicit protective immunity 
against one of the most common PvCSP alleles using soluble recombinant proteins 
expressed by P. pastoris. These recombinant proteins are promising candidates for 
clinical trials aiming to develop a multiallele vaccine against P. vivax malaria.
Keywords: malaria, Plasmodium vivax, recombinant vaccine, circumsporozoite protein, prime-boost regimens
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inTrODUcTiOn
Morbidity due to malaria is prevalent worldwide and is reflected 
by millions of cases every year, which are almost entirely attribut-
able to Plasmodium falciparum and Plasmodium vivax parasite 
species infection (1). P. vivax is the most geographically wide-
spread species of human malaria, predominating in the regions 
of North and South America, South and Southeast Asia, Western 
Pacific, and Eastern Mediterranean; according to the WHO 
2015 World Malaria Report, this malarial species was responsi-
ble for 13.8 million cases worldwide in 2015 (1). Complicated 
malaria and deaths due to P. vivax malaria have been reported 
in different endemic regions (2). Despite the studies on P. vivax 
malaria being neglected in the last few decades (3–5), currently, 
there is a consensus that studies aiming to control and eliminate 
this important tropical disease are of high priority (6). In this 
context, the development of a P. vivax vaccine would represent a 
great advancement in malaria control strategies. Unfortunately, 
only four clinical trials based on the P. vivax antigens (PvDBP, 
ScPvs25, N-R&C peptides and VMP001) have been completed 
according to the NIH website.1
The circumsporozoite protein (CSP) is the most abundant 
component of sporozoite surface and is involved in the initial 
stages of invasion of mammalian host hepatocytes [reviewed 
in Ref. (7, 8)]. As the first protein associated with an effective 
protection against malaria (9, 10), the majority of trials in experi-
mental animals and humans are based on the CSP. This protein 
is an important target for antibodies and CD4+ and CD8+ T cells 
that can eliminate the preerythrocytic stages of the parasite (11). 
RTS,S, the most advanced vaccine so far, directed to the P. falci-
parum CSP, now named as Mosquirix™, is currently scheduled 
to begin a pilot phase in sub-Saharan Africa in 2018, according 
to WHO program (12). This formulation uses the hepatitis B 
surface antigen as a matrix for the conserved C-terminal por-
tion and central repeat domain of CSP combined to powerful 
adjuvant systems (AS), which is a liposomal suspension (AS01) 
presentation of the immunostimulants monophosphoryl lipid A 
(MPL) and saponin purified from Quillaja saponaria (QS21). The 
Phase III efficacy of RTS,S against all malaria episodes between 
children and young infants residents of African endemic areas 
ranges from 28% (three-dose group) to 36% (four-dose group) 
(13). These promising RTS,S results justify investment in the CSP 
as a target for P. vivax vaccines.
As described for the CSPs of other species of Plasmodium, 
the primary structure of P. vivax CSP (PvCSP) has three major 
defined domains. The central repeat domain is flanked by highly 
conserved regions, the N- and C-terminal domains. All three 
domains can be targets of specific antibodies. However, only anti-
bodies directed against the central repeat domain of PvCSP have 
been associated to protective efficacy against P. vivax in Aotus 
nancymaae monkeys (14). Sequencing of the genes encoding the 
CSPs of different strains of P. vivax uncovered the presence of 
three different alleles at the central repeat domain. These alleles 
have been described in different parts of the world (15–19). 
1 https://clinicaltrials.gov.
This strain diversity adds complexity for the development of a 
multiallelic vaccine against P. vivax malaria. The CSPs designated 
VK210, VK247, and P. vivax-like are almost identical in their N- 
and C-terminal domains, but differ in the central repeat region.
P. vivax CSP-derived antigens have been combined into multi-
valent formulations or chimeric synthetic molecules in attempts 
to obtain protective immunity against P. vivax. Recombinant 
PvCSP-derived proteins expressed in Escherichia coli and yeast 
were tested as vaccines with very limited success (20) and thus 
were not pursued further. Peptides based on the N-terminal 
region, central repeats, and C-terminal region of PvCSP-VK210 
formulated in Montanide ISA 720 or Montanide ISA 51 adjuvants 
were immunogenic in BALB/c mice, Aotus monkeys (21), and 
healthy human volunteers (22). Recently, a PvCSP-based vaccine 
named Rv21 was demonstrated to be highly protective against 
challenge in rodent models to malaria (23). However, these vac-
cines did not consider the three allelic variants of PvCSP.
The most advanced recombinant protein formulation for 
P. vivax is the vaccine VMP001 (vivax malaria protein 001) (24). 
VMP001, obtained in bacteria E. coli, merges the central variant 
epitopes of VK210 and VK247 flanked by the amino- and carboxy-
terminal regions of PvCSP, and was immunogenic in C57BL/6 
(25), Rhesus monkeys (26), and human naive volunteers (27). 
The clinical trial results from Phase I/IIa showed VMP001 to be 
immunogenic, inducing humoral and cellular immune responses 
to the vaccine antigen. A significant delay in time to parasitemia 
was seen in 59% of vaccinated subjects compared to the control 
group. However, vaccination did not induce sterile protection 
(27). Immunogenicity to PvCSP was also achieved by our group, 
with E. coli constructs fusing all of the three variants, in C57BL/6 
mice (28, 29). In these studies, the induced antibodies against the 
PvCSP chimeric constructs were able to recognize epitopes from 
each of the variants (VK210, VK247, and P. vivax-like) inserted 
in the central region (28, 29). However, the recombinant PvCSP 
used in these studies were expressed using prokaryotic systems 
as insoluble proteins, complicating large scale production. Thus, 
antigen expression as soluble secreted proteins using eukaryotic 
systems such as Pichia pastoris may represent a long-term advan-
tage in an effort to solve this problem.
Based on these findings, we generated three new recombinant 
proteins based on the central regions of these variants, that con-
tain immunodominant epitopes for B  cells, and the conserved 
C-terminal region of PvCSP. Additionally, we generated a fourth 
recombinant protein, which contains the C-terminal region and 
epitopes from the three P. vivax CSP alleles fused as a single poly-
peptide, called yPvCSP-All epitopes. All recombinant proteins 
were successfully produced as soluble secreted proteins in the 
yeast P. pastoris. The present study describes the immunogenicity 
of the different formulations and analysis for protection against 
the PvCSP-VK210 allele.
MaTerials anD MeThODs
ethics statement
This study was performed in strict accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory 
FigUre 1 | Schematic representation of the Plasmodium vivax 
circumsporozoite protein (CSP) recombinant antigens. The individual 
recombinant proteins have the specific individual repeats [yPvCSP-VK210 
(n = 19), yPvCSP-VK247 (n = 19), or yPvCSP-P. vivax-like (n = 16)] and the 
C-terminal (CT) region. For each repeat sequence, the amino acids positions 
and the histidine tag are indicated. The classic repeat sequence VK210 is 
represented in yellow, VK247 in green, and P. vivax-like in blue. The 
yPvCSP-All epitopes merges the repeats of all three allelic variants describe 
above (n = 6/6/5 repeat sequences of VK210/P. vivax-like/VK247, 
respectively) and the CT region.
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Animals of the Brazilian National Council for the Control 
of Animal Experimentation (CONCEA).2 The protocol was 
approved by the Committees on the Ethics of Animal Experiments 
of the Faculty of Pharmaceutical Sciences of University of São 
Paulo, Brazil (CEUA No. 362/2012), and the Institutional Animal 
Care and Use Committee at the Federal University of Sao Paulo 
(CEP No. 0172/12 and CEUA No. 1463171214). The study with 
human blood obtained from infected Thai patients was approved 
by Oxford Tropical Research Ethics Committee (reference 
OX28-09).
recombinant Proteins expressed  
in P. pastoris Yeast
Genetic Design and Construction  
of yPvCSP Recombinant Proteins
Synthetic genes encoding the recombinant proteins yPvCSP-
VK210, yPvCSP-VK247, yPvCSP-P. vivax-like, and yPvCSP-All 
epitopes were synthetized by GenScript USA, Inc. (Piscataway, 
NJ, USA) using codon optimization to improve expression in 
P. pastoris. Figure 1 shows a schematic representation of these 
2 http://www.mctic.gov.br/mctic/opencms/textogeral/concea.html.
recombinant proteins. The synthetic genes were cloned into 
the pUC57 vector and were subsequently subcloned into the 
P. pastoris expression vector pPIC9K (Invitrogen, Carlsbad, 
CA, USA). Amplified plasmids were linearized with SalI and 
transformed into the GS115 strain (his4−) of P. pastoris by elec-
troporation. Clones transformed with plasmid pPIC9K-PvCSP-
VK210, pPIC9K-PvCSP-VK247, pPIC9K-PvCSP-P. vivax-like, or 
pPIC9K-PvCSP-All epitopes were screened for high copy-number 
integration by G418 selection, according to the manufacturer’s 
instructions (Pichia Expression Kit, Invitrogen).
Expression and Purification of Recombinant Proteins
Clones with a Mut+ phenotype that were secreting high levels of 
each recombinant protein were selected. The induction of protein 
expression was performed as described, with some modifications 
(30). A Mut+ transformant was initially grown overnight in 
200 mL of BMGY medium (1% w/v yeast extract, 2% w/v peptone, 
1.34% w/v yeast nitrogen base without amino acids, 4 × 10−5% 
w/v biotin, 1% w/v glycerol, and 0.1 M potassium phosphate, pH 
6.0) at 28–30°C with vigorous shaking. The cells were harvested, 
resuspended in 1 L BMMY (BMGY with glycerol replaced with 
0.5% v/v methanol), and incubated again for 72  h. Methanol 
was added every 24 h to a final concentration of 1% v/v. After 
induction for 72 h, the cells were removed by centrifugation and 
the culture supernatant was clarified by filtration with a 0.45-µm 
membrane (Merck Millipore, MA, USA). The supernatant was 
applied to a HisTrap FF column coupled to a FPLC ÄKTA prime 
plus (GE Healthcare, Chicago, IL, USA), which was previously 
equilibrated with 20  mM sodium phosphate/0.5  M NaCl, pH 
8.0. Bound proteins were eluted with a 0–500  mM imidazole 
(Sigma-Aldrich, St. Louis, MO, USA) gradient in 20 mM sodium 
phosphate/0.5 M NaCl, pH 8.0. Fractions containing protein were 
detected by SDS-PAGE and Coomassie blue staining, pooled, and 
used in a second-purification step by anionic exchange chroma-
tography using a Resource Q column coupled to a FPLC ÄKTA 
prime plus (GE Healthcare, Chicago, IL, USA). The protein was 
eluted using a 0–1 M NaCl linear gradient in 20 mM Tris–HCl, 
pH 8.0, and analyzed by SDS-PAGE. The peaks corresponding to 
each recombinant protein that had a high degree of purity were 
collected and dialyzed against phosphate-buffered saline (PBS). 
The protein concentration was determined by the Bradford 
method (BioRad, Hercules, CA, USA) using bovine serum 
albumin (BSA; Sigma-Aldrich, St. Louis, CA, USA) as a standard.
characterization of recombinant yPvcsP
Immunoblotting
For immunologic characterization, the recombinant proteins 
were fractionated by 12% SDS-PAGE under reducing conditions 
and were transferred from the gel to nitrocellulose membranes 
(Hybond N, GE Healthcare, Chicago, IL, USA). The membranes 
were blocked for up to 1 h using fat free milk in PBS (5% w/vol) 
and bovine serum albumin (2% w/vol) containing 0.1% Tween 20 
(PBS-T). The blots were incubated for 1 h at room temperature 
(RT) with the appropriate primary antibody diluted in PBS-T, 
as described (31). The primary antibodies used were (i) mouse 
monoclonal antibodies (MAbs) to His6 (GE Healthcare, Chicago, 
IL, USA) diluted 1:1,000; (ii) MAb 2F2 (MRA-184) to PvCSP from 
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the VK210 strain (1 µg/mL) (32); and (iii) MAb 2E10E9 (MRA-
185) to PvCSP from the VK247 strain (1 µg/mL) developed by 
Dr. Alan Cochrane (Unpublished data). The hybridomas used for 
the production of MRA-184 and MRA-185 were obtained from 
the Malaria Research and Reference Reagent Resource Center 
(MR4), Manassas, VA, USA.
After washing twice with PBS-T, peroxidase-labeled goat 
anti-mouse IgG (Sigma-Aldrich, St. Louis, MO, USA) diluted 
1:1,000 in PBS-T was added for 1 h. The reaction was developed 
using a chemiluminescence detection assay (ECL, GE Healthcare, 
Chicago, IL, USA).
Reverse-Phase High-Performance Liquid 
Chromatography (RP-HPLC)
Purified proteins were analyzed by RP-HPLC using a C18 col-
umn (4.6 × 250 mm; 300 µm particle size) coupled to an HPLC 
LCMS-2020 LC/MS system (Shimadzu, Kyoto, Japan). The HPLC 
procedure was performed at RT (≈25°C) using a binary gradient 
of 0.1% trifluoroacetic acid (TFA, Solvent A) and 0.1% TFA in 
a 9:1 (v/v) solution of acetonitrile:water (Solvent B) with a two-
step solvent gradient starting at 0–20%, followed by 20–100%, at 
a rate of 1 mL/min for 40 min. The elution was monitored with 
a UV-Visible absorbance detector (Shimadzu SPD M20A) at 220 
and 280 nm.
recombinant Proteins expressed in E. coli
In order to determine the specificity of IgG antibodies, 
flagellin-fusion proteins His6FliC-PvCS-VK210 (31), His6FliC-
PvCS-VK247 and His6FliC-PvCS-P. vivax-like (28), were used 
individually on ELISA plates for analyzing the specificity of the 
antibodies against each of the repeats sequences, as these proteins 
do not have the C-terminal region. The His6FliC protein (31), used 
as a carrier for the individual repeat sequences, is a recombinant 
flagellin derived from Salmonella Typhimurium and produced 
in E. coli. In order to determine the specificity of the antibodies 
against C-terminal region, No repeats protein (29) was used. This 
recombinant protein contains only the PvCSP N-terminal region 
fused with the C-terminal region.
These recombinant proteins were produced in E. coli using the 
method previously described (33). Following this, purification was 
performed by affinity chromatography (HisTrap FF column, GE 
Healthcare, Chicago, IL, USA) and subsequent anion-exchange 
chromatography (Resource Q column, GE Healthcare, Chicago, 
IL, USA) as described above.
immunization schedule
For immunological assays, 6–8 weeks old C57BL/6 female mice 
were subcutaneously (s.c.) immunized thrice, following the 
schedule described in the figures (n =  6 mice per group). For 
each dose, the indicated amount of protein was administered 
with high-molecular-weight Poly(I:C) adjuvant (50  μg/dose/
mouse) (InvivoGen, San Diego, CA, USA). A volume of 50 µL 
was injected s.c. into each footpad (first dose) and a final volume 
of 100 µL was injected s.c. at the base of the tail (second and third 
doses). After each immunization, blood was collected from the 
tail, and the sera were analyzed for the presence of antibodies 
against each recombinant protein. For the protection experiment, 
mice were intraperitoneally immunized thrice, following the 
schedule described in Figure 8A.
immunological assays
Antibody Measurement
Antibodies against each recombinant protein in mouse sera 
were detected by enzyme-linked immunosorbent assay (ELISA), 
as described previously (29). The recombinant proteins were 
employed as solid phase-bound antigens (200 ng/well), and a vol-
ume of 50 µL of each solution was added to each well of a 96-well 
plate. After overnight incubation at RT, plates were washed with 
a solution of PBS and 0.05% PBS-T and blocked with a solution 
of PBS, 2.5% (w/v) skimmed milk, and 2.5% BSA for 2 h at 37°C. 
Serial dilutions (1/2) of murine polyclonal sera (100  µL) were 
added to wells in duplicate, followed by incubation for 1  h at 
37°C. After washing with PBS-T, 50 µL aliquots of peroxidase-
labeled goat anti-mouse IgG (Sigma, St. Louis, MO, USA), diluted 
1:1,000, were added to each well and incubated for 1 h at 37°C. 
The enzymatic reaction was developed with o-phenylenediamine 
(1 mg/mL) (Sigma) diluted in phosphate-citrate buffer (pH 5.0) 
containing hydrogen peroxide [0.03% (vol/vol)]. The enzymatic 
reaction was stopped by the addition of 50  µL of a solution 
containing 4  N H2SO4. The optical density at 492  nm (OD492) 
was measured using a SpectraMax Plus 384 Microplate Reader. 
Anti-PvCSP titers were determined based on the highest dilution 
of sera that yielded an A492 higher than 0.1. This cut-off value was 
set at 3 SDs above the mean A492 obtained from naïve mice against 
the recombinant proteins.
For detection of IgG subclass responses, secondary antibodies 
specific to mouse IgG1, IgG2b, and IgG2c were used (Southern 
Technologies, Chattanooga, TN, USA). Results are expressed as 
the mean values of IgG titers ± SD.
Immunofluorescence Assay
Anopheles cracens mosquitoes were fed on human blood obtained 
from infected Thai patients using Hemotek® membrane-feeding 
system (34). After 2 weeks, aseptically dissected infected salivary 
glands were disrupted in a glass tissue grinder and the sporozoite 
preparation was deposited on glass slides. Slides were dried at RT 
and kept frozen at −20°C before use.
Slides containing wild-type VK210 P. vivax sporozoites were 
fixed with cold methanol for 10 min and blocked with PBS–3% 
BSA for 30  min at RT. Slides were then incubated in a humid 
chamber for 1 h at RT with sera from mice immunized with the 
mix of the three CSP alleles (VK210, VK247, and P. vivax-like) or 
with the yPvCSP-All epitopes recombinant protein (dilution 1:100 
in PBS–3% BSA). MAb 2F2 (anti-PvCSP-VK210) and sera from 
mice immunized with adjuvant only (dilution 1:50 in PBS–3% 
BSA) were used as a positive and negative controls, respectively. 
Slides were washed three times with PBS-T before the addition 
of a dilution 1:500 in PBS–3% BSA of anti-mouse IgG conjugated 
to Alexa Flour 568 (Thermo Fisher Scientific, Waltham, MA, 
USA). The slides were incubated for 1 h at RT, washed three times 
with PBS-T and incubated for 15  min with 4′,6-Diamidino-2-
Phenylindole Dihydrochloride (DAPI, Invitrogen, Carlsbad, CA, 
USA). Binding was visualized using a fluorescence microscope 
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DMI6000B/AF6000 (Leica) coupled to a digital camera system 
(DFC 365 FX) and the images were treated and analyzed using 
the open-source software ImageJ.
Cytokine Measurement
To measure the number of cells secreting interferon gamma 
(IFN-γ), splenocytes collected from immunized C57BL/6 mice 
were used for enzyme-linked immunospot (ELISPOT) assays. 
This procedure was performed by using mouse IFN-γ capture 
antibody (BD Biosciences) to coat flat-bottom Multiscreen HTS 
plates (Millipore) overnight at 4°C. After three washes with 
PBS-T, the plates were blocked with R10 [(fetal calf serum (10%) 
(v/v), RPMI 1640), Gibco], for 2  h at 37°C and 5 ×  105 cells/
well mice splenocytes were stimulated overnight at 37°C, 5% 
CO2, in the presence of recombinant proteins (yPvCSP-VK210, 
yPvCSP-VK247, yPvCSP-P. vivax-like, and yPvCSP-All epitopes, 
10  mg/mL) or ConA (2.5  mg/mL) diluted in RPMI 1640-IL2 
[IL-2 0.03% (v/v)]. Plates were then washed 3 times with PBS, 
and mouse IFN-γ detection antibody biotinylated [XMG 1.2, 
(1:200), Pharmingen] was added to the plates overnight at 4°C. 
Streptavidin-labeled peroxidase [(1:500), BD, Biosciences] was 
added to the plates, after six PBS-T washes, for 2 h and spots were 
visualized with 4′,6-diamidino-2-phenylindole, dihydrochloride 
(1 mg/mL).
To determine the intracellular expression of IFN-γ and 
tumor necrosis factor alpha (TNF-α), intracellular cytokine 
staining (ICS) was used. These assays were performed as in 
previous studies (29, 35). Basically, ICS was evaluated following 
the in vitro culture of splenocytes in the presence or absence of 
an antigenic stimulus. Cells were washed three times in RPMI 
1640 medium (pH 7.4) and resuspended in cell culture medium 
consisting of RPMI 1640 medium (pH 7.4) supplemented with 
10 mM HEPES, 0.2% sodium bicarbonate, 59 mg/L of penicil-
lin, 133  mg/L of streptomycin, and 10% fetal bovine serum 
(Hyclone, Logan, UT, USA). Cell viability was evaluated using 
0.2% trypan blue exclusion dye. Cell density was adjusted to 
5 ×  106  cells/mL in cell culture media containing anti-CD28 
(2 µg/mL), BDGolgiPlug (10 µg/mL), monensin (5 µg/mL), and 
FITC-labeled anti-CD107a (2  µg/mL). Final concentrations of 
10 µg/mL of the indicated recombinant proteins or 2 µg/mL of 
Concanavalin A (ConA; Sigma-Aldrich, St. Louis, MO, USA) 
were added. The cells were cultivated in V-bottom 96-well plates 
(Corning, New York, NY, USA) in a final volume of 200 µL in 
duplicate, at 37°C in a humid environment containing 5% CO2. 
After a 12 h incubation, cells were stained for surface markers 
with PerCP-Cy5.5-labeled anti-CD4 (clone RM4-5) or PECy7-
labeled CD8 (clone 53-6.7) on ice for 20 min. To detect IFN-γ 
and TNF-α by intracellular staining, cells were then washed 
twice in PBS/0.5% BSA/2 mM EDTA, fixed and permeabilized 
with BD Fixation/Permeabilization solution. Cells were stained 
for intracellular markers using APC-labeled anti-IFN-γ (Clone 
XMG1.2) and PE-labeled anti-TNF-α (clone MP6-XT22). Finally, 
cells were washed twice with BD perm/wash buffer and fixed in 
1% PBS-paraformaldehyde. At least 50,000 cells were acquired 
on a BD FACS Canto II flow cytometer and then analyzed with 
FlowJo 8.7 software. Gating strategy is depicted in Figure S1 in 
Supplementary Material.
Mice infection and Parasitemia analysis
Sporozoites (spz) from Plasmodium berghei ANKA expressing 
P. vivax circumsporozoite VK210 repeats (Pb/PvVK210) were 
obtained as described elsewhere (36). Transgenic Pb/PvVK210 
spz were maintained in female Anopheles stephensi mosquitoes. 
The total number of spz was determined using a Kova glass slide 
and 4,000 spz in 1 μL of PBS were microinjected s.c. in the foot-
pad of C57BL/6 mice previously immunized as described above. 
Thin-blood smears were prepared daily from day 3 to day 10 after 
challenge, on glass slides from a drop of blood obtained from tails. 
Blood smears were air-dried, fixed with methanol, and Giemsa 
stained. Percentages of parasitized erythrocytes were determined 
by microscopic examination of ~3,000 erythrocytes each in 
Giemsa-stained smears.
For analysis of the hepatic infection, livers of immunized 
mice were harvested 42 h after sporozoite challenge and frozen 
in liquid nitrogen. Ground tissue was resuspended in Trizol 
reagent (Invitrogen) and total RNA was extracted accord-
ing to the manufacturer’s instructions. After treatment with 
turboDNase (Ambion), 2  µg of total RNA was used for cDNA 
synthesis, using the superscript II reverse transcriptase and ran-
dom primers (d(N)9, New England Biolabs). For each sample, 
a reaction without reverse transcriptase was used for control-
ling DNA contamination. The real time PCR was performed 
with 1/20 of the cDNA reaction using the iTaq Universal SYBR 
Green Supermix (Biorad) and the primers for the mouse HPRT 
(Fwd, 5′-CCTGCTGGATTACATTAAAGCACTG-3′; Rev5′-
GTCAAGGGCATATCCAACAAC-3′) or for the P. berghei 18S 
rRNA (Fwd, 5′-AAGCATTAAATAAAGCGAATACATCCT 
TAC-3′; Rev, 5′-GGAGATTGGTTTTGACGTTTATGTG-3′). 
Reactions were run in triplicate in three independent experi-
ments according to the following conditions: (1 × 95°C for 5 min; 
40 × 95°C for 15 s, 60°C for 30 s; 1 × 55°C to 95°C in 13 min).
statistical analysis
For immunological responses analyses, values were log-
transformed and compared using one-way ANOVA followed by 
Tukey’s HSD tests.3 For parasitemia analyses, the non-parametric 
Mann–Whitney test was performed. Differences were considered 
statistically significant when P < 0.05.
resUlTs
Four recombinant Proteins Based  
on the sequences of P. vivax csPs Were 
successfully Produced in the Yeast  
P. pastoris as soluble secreted Proteins
Recombinant proteins representing the PvCSP alleles (VK210, 
VK247, and P. vivax-like) as well as the hybrid polypeptide 
yPvCSP-All epitopes were generated. This hybrid contained 
the conserved C-terminal of the P. vivax CSP and the three 
variant repeat domains in tandem. The proteins were purified 
and their integrity and purity was evaluated by SDS-PAGE, 
3 http://faculty.vassar.edu/lowry/VassarStats.html.
FigUre 2 | Purification and biochemical characterization of the Plasmodium vivax circumsporozoite protein (CSP) recombinant proteins. (a) 13% SDS-PAGE under 
reduced conditions stained with Coomassie blue. Proteins migrate between 50 and 55 kDa. Fractions were 2 µg of: (1) yPvCSP-VK210, (2) yPvCSP-VK247,  
(3) yPvCSP-P. vivax-like, and (4) yPvCSP-All epitopes. (B) Western blot using 1 µg of the same fractions of proteins described above. Antibodies used were 
monoclonal antibody (MAb) anti-His, MAb VK210 (2F2), and MAb VK247 (2E10.E9). The secondary antibody used was anti-mouse IgG HRP-labeled, and detection 
was performed by ECL assay. (c) The purity of proteins, after the combination of chromatographic methods, was analyzed by reverse-phase high-performance 
liquid chromatography (RP-HPLC), in which the gradient elution was developed combining 0.1% trifluoroacetic acid (TFA) in water and 0.1% TFA in 90% acetonitrile, 
24°C, 1 mL/min for 40 min, in a C18 column.
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immunoblotting, and RP-HPLC (Figure  2). A reduced gel 
stained with Coomassie blue showed that the proteins migrated 
between 40 and 55 kDa (Figure 2A). Figure 2B shows that the 
purified proteins were recognized by specific MAbs generated 
against radiation-attenuated P. vivax sporozoites (MAb VK210 
2F2 and MAb VK247 2E10.E9), as well as monoclonal anti-His 
antibody. Recognition was also observed for the entire hybrid 
polypeptide. The purity of the proteins, after the combination of 
FigUre 3 | Specific antibody response in mice immunized with Plasmodium vivax circumsporozoite protein (PvCSP) recombinants. (a) C57BL/6 mice were 
immunized s.c. with three doses 28 days apart with the purified proteins in the presence of the adjuvant Poly(I:C), whereby the antibody response was analyzed 
according to the timeline described. (B) The IgG antibody serum titers against recombinant proteins representing each allelic form of PvCSP were analyzed by 
ELISA. The results are expressed as the means ± SD (n = 6). Mouse groups were immunized with: (1) Poly(I:C); (2) Poly(I:C) plus yPvCSP-VK210  
(1 μg/dose/mouse); (3) Poly(I:C) plus yPvCSP-VK247 (1 μg/dose/mouse); (4) Poly(I:C) plus yPvCSP-P. vivax-like (1 μg/dose/mouse); (5) Poly(I:C) plus a protein mix  
[yPvCSP-VK210 (1 μg/dose/mouse) + yPvCSP-VK247 (1 μg/dose/mouse) + yPvCSP-P. vivax-like (1 μg/dose/mouse)]; or (6) Poly(I:C) plus yPvCSP-All epitopes 
(3 μg/dose/mouse). (c) IgG isotypes were determined by ELISA in sera of mice from groups 5 and 6 described above. Asterisk denotes statistical differences 
(P < 0.01) when comparing IgG1 isotype with IgG2b, IgG2c and IgG3.
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chromatographic methods, was analyzed by RP-HPLC. Analysis 
of RP-HPLC chromatograms revealed high purity of these 
recombinant proteins (Figure 2C).
Vaccine containing the Three allelic 
Forms of the P. vivax csP Was 
immunogenic in Mice
The serum IgG responses to PvCSP antigens were determined 
in C57BL/6 mice immunized s.c. with the purified proteins in 
the presence of the adjuvant Poly(I:C). Six mice per group were 
immunized with three doses containing 1 µg of each protein or 
adjuvant alone administered as described in Section “Materials 
and Methods,” at 28-day intervals. Formulations containing the 
mix of the three CSP alleles (VK210, VK247, and P. vivax-like, 
1  µg of each protein/animal/dose) or the hybrid polypeptide 
(yPvCSP-All epitopes, 3  µg of protein/animal/dose) were also 
tested. The antibody titers were analyzed by ELISA according to 
the timeline described in Figure 3A. These homologous prime-
boost vaccination regimens were highly immunogenic in the 
mouse model, eliciting a high and long-lasting specific antibody 
immune response (Figure 3B).
To better characterize the anti-PvCSP response, the IgG sub-
types of the generated antibodies were analyzed and the IgG1/
IgG2c ratio was calculated. All mouse sera presented detectable 
levels of all IgGs in the groups immunized with the proteins 
FigUre 4 | Specificity of IgG antibody in mice immunized with Plasmodium vivax circumsporozoite protein (CSP) recombinants. (a) Schematic representation of 
recombinant proteins used as a substrate bound to the plates in the ELISA assay. (B) C57BL/6 mice were immunized s.c. with the purified proteins in the presence 
of the adjuvant Poly(I:C) according to the timeline described in Figure 3a. The specificity of IgG antibody serum titers toward rFliC, FliC-PvCSP-repeats and No 
repeats proteins were analyzed by ELISA in sera of mice from groups 2 to 6 described in Figure 3B. The results are expressed as mean ± SD (n = 6 animals/
group). P values are indicated. Differences were considered statistically significant when P < 0.05.
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individually, mixed, or fused. An analysis of the IgG1/IgG2c anti-
PvCSP-VK210 ratio (Figure  3C), showed a polarized Th2-like 
response (IgG1/IgG2c > 1). Similar results were observed against 
PvCSP-VK247 (data not shown).
To delineate the specificity of anti-yPvCSP-All epitopes 
antibodies, when compared with immunizations performed with 
individual yPvCSP proteins or protein mix, the mouse serum 
was tested against three recombinant proteins containing only 
the repeats fused to flagellin (FliC) of Salmonella enterica serovar 
Typhimurium [FliC-PvCSP-repeats (28)], and one recombinant 
protein containing only PvCSP N- and C-terminal regions [No 
repeats (29)] (Figure 4A). Interestingly, all FliC-PvCSP-repeats 
variants and the No-repeats protein were recognized in sera from 
mice immunized with protein mix or with yPvCSP-All epitopes, 
whereas no significative cross-reaction among repeat sequences 
was observed in animals immunized with individual yPvCSP 
proteins (Figure 4B). We concluded that the immunization with 
a recombinant protein expressing all the three different allelic 
variants in fusion elicited high IgG antibody titers reacting with 
all three different allelic variants of PvCSP. The antibodies were 
targeted to both the C-terminal and the repeat domains of PvCSP.
In addition, we determined whether sera from mice immu-
nized with the prime-boost immunization regimen reacted with 
P. vivax sporozoites in immunofluorescence assays. We observed 
that sera from both groups of mice that were immunized with 
a formulation containing the yPvCSP-All epitopes and protein 
mixture reacted to sporozoites of the P. vivax VK210 strain 
(Figures 5A,B). Antibody recognition was specific, as control sera 
from mice immunized with the adjuvant Poly(I:C) did not react 
(Figure 5C), and the sera-stained sporozoites showed a pattern of 
staining on the surface of the sporozoites similar to that observed 
with the monoclonal antibody anti-VK210 (Figure 5D).
FigUre 5 | Recognition of native protein in Plasmodium vivax isolates. 
Indirect immunofluorescence analysis was performed using pool of sera 
(diluted 1:100) from C57BL/6 mice immunized with (a) yPvCSP-All epitopes, 
(B) protein mixture or (c) phosphate-buffered saline (PBS) in adjuvant, as a 
negative control. (D) As a control positive anti-PvCSP-VK210 (MAb 2F2) was 
used. Microscope slides containing wild-type P. vivax were obtained from 
Thailand isolates. Antibody binding was detected with secondary Alexa 
568-labeled antibody (red) and nuclei were visualized by DAPI staining.
FigUre 6 | Interferon gamma (IFN-γ)-producing cells in mice immunized with 
recombinant proteins. (a) C57BL/6 mice were immunized following the 
scheme with yPvCSP-All epitopes (3 μg/mouse) or a mix of yPvCSP-
VK210 + yPvCSP-VK247 + yPvCSP-P. vivax-like (1 μg/each protein/mouse), 
in the presence of the adjuvant Poly(I:C). (B) To measure the number of cells 
secreting IFN-γ, splenocytes collected from immunized C57BL/6 mice on day 
40 after priming were used for enzyme-linked immunospot (ELISPOT) assays. 
The recombinant proteins yPvCSP-VK210 (yVK210), yPvCSP-VK247 
(yVK247), yPvCSP-P. vivax-like (yVL), and yPvCS-All epitopes (yAll epitopes) 
were used as stimuli (10 µg/mL). SFC, spot forming cells. Asterisk denotes 
statistical differences (P < 0.05).
9
Gimenez et al. P. vivax Malaria Vaccine
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1275
yPvcsP-all epitopes and Protein Mix 
induced low activation of cD4+  
and cD8+ T cells
We selected two vaccine formulations (yPvCSP-All epitopes and 
protein mix) to evaluate the ability of the induction of the T cell-
mediated immune responses in immunized C57BL/6 mice. We 
measured IFN-γ secretion by ELISPOT assay. We also evaluated 
the production of inflammatory cytokines (IFN-γ and TNF-α) by 
CD4+ and CD8+ T cells using ICS. Figure 6A shows a schematic 
representation of the immunization schedule. Spleen cells were 
stimulated in  vitro with recombinant proteins representing the 
three allelic forms of PvCSP.
Overall, very low levels of CD4+ and CD8+ T  cells produc-
ing any cytokine were detected. Positive controls performed in 
parallel with stimulation with ConA were consistently successful 
(data not shown). A higher number of IFN-γ-producing cells 
were observed in the group immunized with the protein mix 
and stimulated with recombinant yPvCSP-VK247, but not in 
the animals immunized with the yPvCSP-All epitopes when the 
splenocytes were stimulated with the same protein (Figure 6B). 
This difference is in agreement with previous results (29) and 
could be due to a different processing or antigen presentation of 
the VK247 epitope.
We also attempted to detect IFN-γ and TNF-α using ICS 
(Figure 7). Using Boolean gating analysis, we were able to detect 
low but significant simultaneous production of both cytokines 
by CD4+ T cells derived from mice immunized with the protein 
mix in a splenocyte culture restimulated with yPvCSP-VK247 
recombinant protein (Figure 7A). We also observed that CD8+ 
T cells derived from mice immunized with the protein yPvCSP-
All epitopes were able to produce low but significant levels of 
TNF-α in a splenocyte culture pulsed with the antigen yPvCSP-
P. vivax-like (Figure 7B). On the other hand, we did not detect 
any specific responses (IFN-γ or TNF-α) in CD4+ or CD8+ T cells 
after restimulation with recombinant yPvCSP-VK210.
Similarly, we attempt to detect a cytotoxic response in vac-
cinated mice by measuring CD107a expression in CD4+ or CD8+ 
T cells after stimulation with the recombinant proteins. Under the 
experimental conditions, we did not detect significant differences 
in CD107a expression when compared to mice immunized with 
adjuvant only (Figure S2 in Supplementary Material).
FigUre 7 | CD4+ and CD8+ T cell-mediated immunity of mice immunized with recombinant proteins. C57BL/6 mice were immunized s.c. with the recombinant 
proteins following the scheme described in Figure 6a. To determine the intracellular expression of interferon gamma (IFN-γ) and tumor necrosis factor alpha 
(TNF-α), intracellular cytokine staining (ICS) was performed following the in vitro culture of splenocytes in the presence or absence of the antigenic stimuli yPvCSP-
VK210 (yVK210), yPvCSP-VK247 (yVK247), and yPvCSP-P. vivax-like (yVL). (a) Frequency of CD4+ cytokine-producing cells. (B) Frequency of CD8+ cytokine-
producing cells. Asterisks denote statistically significant (P < 0.05) higher frequencies of cells from mice immunized with the recombinant proteins when compared 
to cells from mice injected with adjuvant only. Media backgrounds of all samples were subtracted before plotting.
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a Vaccine containing the Three allelic 
Forms of the P. vivax csP induces 
Protection against infection in Mice  
after challenge with chimeric Parasite  
Pb/PvVK210
We used the chimeric parasite Pb/PvVK210, in which the repeats 
of the PbCSP were replaced by those of the PvCSP (VK210), to 
evaluate the potential efficacy of the yPvCSP-All epitopes vaccine 
against a sporozoite infection in vivo. C57BL/6 mice were immu-
nized with yPvCSP-All epitopes in the presence of Poly(I:C), in a 
three-dose prime-boost immunization regimen (Figure 8A). The 
immunization-challenge schedule is described in Figure 8A.
This experimental design involved challenge with 4,000 Pb/
PvVK210 sporozoites on day 25 after boost. As shown in Figure 8B, 
the immunization with three doses of 5 µg of protein/mouse/dose 
was protective for 4/6 mice until day 10 postchallenge, whereas all 
control mice became infected by day 4 postchallenge. This protec-
tion corresponded to a ~10-fold decrease in parasitemia at day 5, 
when infected blood cells in mice that only received adjuvant still 
increase exponentially (Figure 8C, P = 0.0095).
Finally, we evaluated the liver stage parasite burden in immu-
nized mice challenged with Pb/PvVK210 sporozoites. The liver 
parasite burdens in mice group immunized with a mixture of 
Poly(I:C) plus 5 µg of yPvCSP-All epitopes was 20 times lower 
compared with control group that received Poly(I:C) alone 
(P = 0.0159) (Figure 8D).
DiscUssiOn
In the past decade, diverse efforts toward the development of an 
effective vaccine against malaria have increased the knowledge 
FigUre 8 | Protection against experimental challenge in mice immunized with a prime-boost regimen. (a) C57BL/6 mice were immunized i.p. with Poly(I:C) or a 
mixture of Poly(I:C) plus 5 µg of yPvCSP-All epitopes following the scheme described. On day 67 after priming, mice were challenged with 4,000 Pb/PvVK210 
transgenic sporozoites. (B) Parasitemia was analyzed by Giemsa-stained blood smears on the following 10 days. Percentage of non-infected mice in each 
experimental group are shown. (c) Log of parasitemia at day 5 (D5) postchallenge measured in mice immunized with Poly(I:C) (n = 4) or a mixture of Poly(I:C) plus 
5 µg of yPvCSP-All epitopes (n = 6). (**) P = 0.0095. (D) The liver load was evaluated by RT-PCR. The infection level in liver in mice immunized with a mixture of 
Poly(I:C) plus 5 µg of yPvCSP-All epitopes (n = 5) is compared with control group that received Poly(I:C) alone (n = 4). (*) P = 0.0159. C-terminal (CT) differences 
(delta CT) between the mouse HPRT and Pb 18S CT values are shown.
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about the level of protection necessary—although also often 
not enough—to achieve disease-preventative immunity. For 
preerythrocytic vaccines, there is a consensus on the require-
ment of high serum levels of IgG antibodies specific to the repeat 
sequences of the CSP antigen, both for P. falciparum and for 
P. vivax. In addition, protection has been related to the frequency 
of CD4+ T  cells expressing proinflammatory cytokines; thus, 
several approaches have been trialed in order to produce both a 
strong antibody response and cell-mediated immunity.
In several studies focusing on RTS,S formulations, the 
generation of antibodies against the central repeat region 
of P. falciparum CSP has been recognized as key factor to 
achieve some level of protective effect [reviewed in Ref. (11)]. 
Accordingly, ELISA titers to the CSP repeats are significantly 
higher in protected individuals, whereas opsonizing antibodies 
would not contribute to protection and the C-terminal-targeted 
antibody contribution remains undefined (37).
In P. vivax, the development of a vaccine targeting the CSP 
antigen has been limited for several decades to preclinical immu-
nization models developed mostly in mice. In previous works, we 
were able to successfully elicit high titers of antibodies recognizing 
the three allelic forms of the PvCSP antigen, by using homolo-
gous or heterologous prime-boost immunization regimens (29). 
These immunizations were carried out using the same adjuvant 
employed here, Poly(I:C), which is a synthetic analog of double-
stranded RNA capable of activating toll-like receptor type 3 
and therefore eliciting a virus-like immune response in humans 
(38). However, the recombinant protein expression from the 
bacterial system yielded high levels of unfolded protein, mostly 
recovered from inclusion bodies, which have to be denatured to 
obtain purified proteins. These production difficulties led us to 
develop novel CSP-based recombinant proteins to be expressed 
in a eukaryotic system such as P. pastoris. Our group has been 
employing this protein-production system successfully for the 
last few years, enabling the easy production of highly purified, 
stable, properly folded, and immunogenic proteins to be used 
for the development of vaccines against protozoa parasites (30, 
39). These features, also shown in this work, would be a great 
advantage for the following scaling process in order to obtain 
a vaccine formulation, which could be distributed in several 
endemic areas.
Recently, results from the first in-human clinical trial aiming 
to develop a vaccine against P. vivax (VMP001) were published. 
This formulation contains a recombinant protein comprising 
N-terminal, C-terminal, VK210, and VK247 repeat domains. 
As mentioned, vaccination did not induce sterile protection; 
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however, a significant delay in the prepatent period was associated 
with the presence of anti-VK210 repeats-specific responses (27).
Interestingly, although specific antibodies were generated 
against all regions of the CSP in all vaccinated individuals, CD4+ 
T cell responses specific to repeat and C-terminal regions were 
detected in only 17% of vaccinated subjects, whereas 90% of sub-
jects showed strong cellular responses to the N-terminal region 
(27). As this response was not protective against natural challenge 
(i.e., infected-mosquito bites), we think that immunodominant 
epitopes of the P. vivax CSP-N-terminal region could be hamper-
ing the recognition or antigen presentation of repeat-specific 
domains. Therefore, the absence of the N-terminal region in our 
formulations, which were able to induce a repeat-specific anti-
body and cellular responses in mice, could present an advantage 
when compared to VMP001 formulations.
To our knowledge, this is the first report of a vaccine poten-
tially protective against all the three allelic variants of P. vivax 
CSP. The results presented herein show that immunization with 
our recombinant proteins was able to induce a strong humoral 
immune response, eliciting Abs against all three repeat regions 
as well against C-terminal region. Although immunization with 
single variants generated antibodies with some level of cross-
reaction between the different variants of PvCSP, we showed in 
previous studies that the cross-reactivity between IgG antibodies 
is very limited and would not be possible to use a single variant as 
a universal vaccine (28). Furthermore, cross-reactivity is expected 
to be due essentially to Abs recognizing the C-terminal region, 
present in all the proteins. As Abs against the repeat regions of 
PvCSP were demonstrated to be associated to protection in A. 
nancymaae monkeys (14), the vaccine formulation containing 
the hybrid polypeptide (yPvCS-All epitopes) was selected for 
protection assays, aiming at further development of an anti-P. 
vivax vaccine. The relevant proportion of the antibody titer 
specific for each of the repeat regions induced by immunization 
with yPvCSP-All epitopes indicates that one (instead of three) 
stable protein could be able to confer protection against all the 
three allelic variants of P. vivax sporozoites.
The precise reason why the All epitopes vaccine elicited a 
very low cytokine response measured in the ICS assay and an 
undetectable response in the ELISpot assay is not clear to date. 
A challenging objective of future works will be to find adjuvants, 
delivering systems or expression strategies able to improve CSP-
specific cellular responses. Combined use of viral vectors and 
potent adjuvants was recently reported to improve CD8+ T cell 
responses against preerythrocytic malaria (40). We are cur-
rently working on some of these strategies using new adjuvants, 
adenovirus-delivered antigens and Virus-like particles formula-
tions in order to further develop cell-mediated responses.
In summary, the strong humoral response showed in this 
work, with a significant (>104) proportion of antibodies targeting 
repeats sequences, and the low but detectable CD4+ and CD8+ 
T cell-mediated responses, indicate that this formulation should 
be highly immunogenic in humans, generating immunity to all 
three variants of PvCSP. Furthermore, the significant protection 
elicited after challenge with 4,000 Pb/PvVK210 sporozoites 
should indicate a more effective protection against natural infec-
tion, in which ~100 sporozoites are released per bite (41).
Although the protection found here was not sterilizing to all 
animals, it has been hypothesized that a candidate P. vivax vac-
cine with low efficacy against primary infection may potentially 
reduce transmission by preventing relapses (42). In addition, still 
it is possible to improve the protective immunity of the recombi-
nant vaccine yPvCSP-All epitopes combining with other potent 
adjuvants (Adjuvant Systems) (43). Taken together, our results 
are encouraging for testing our vaccine formulations in clinical 
trials, aiming to the development of a multi-allelic vaccine against 
P. vivax malaria.
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